nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2023-5-109-116nnp-2112Research ArticleREVIEWSОБЗОРЫProblems in the selection of effective analgesics for migraineПроблемы выбора эффективного обезболивания при мигрениhttps://orcid.org/0000-0002-3833-532XТабееваГ. Р.TabeevaG. R.

Гюзяль Рафкатовна Табеева - кафедра нервных болезней и нейрохирургии.

119021, Москва, ул. Россолимо, 11, стр. 1

Gyuzyal Rafkatovna Tabeeva - Department of Nervous Diseases and Neurosurgery.

11, Rossolimo St., Build. 1, Moscow 119021

grtabeeva@gmail.comИнститута клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияN.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Russian Federation202323102023155109116Copyright © Tabeeva G.R., 20232023Табеева Г.Р.Tabeeva G.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2112

Pharmacologic symptomatic treatment of headache attacks is an essential strategy for effective management of patients with migraine. Choosing a medication requires an individualized approach and consideration of patient profile, characteristics of ictal manifestations of migraine, and personal experience in headache relief. Among the recommended medications, triptans are the first choice therapy. The pharmacologic differences among triptans allow selection of the most effective drug depending on the individual needs of the patient. Considering the primary importance of characteristics such as speed and duration of pain relief, as well as the consistency of effect in interrupting successive attacks, the choice of rizatriptan may be optimal for migraine patients.

Фармакологическая симптоматическая терапия приступов головной боли является неотъемлемой стратегией эффективного ведения пациентов с мигренью. Выбор лекарственного средства требует индивидуального подхода и учета профиля пациента, особенностей иктальных проявлений мигрени и персонального опыта купирования головной боли. В ряду рекомендованных лекарственных средств триптаны являются первой линией терапии. Фармакологические различия между триптанами позволяют выбрать наиболее эффективный препарат, основываясь на индивидуальных потребностях пациента. Учитывая приоритетное значение таких характеристик, как скорость и длительность обезболивания, постоянство эффекта при купировании последовательных приступов, выбор ризатриптана может быть оптимальным для пациентов с мигренью.

мигренькупирование приступов мигренитриптаныризатриптанmigrainerelief of migraine attackstriptansrizatriptanСтатья спонсируется компанией «НоваМедика»This article has been supported by NovaMedicaReferencesAmiri P, Kazeminasab S, Nejadghaderi SA, et al. Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front Neurol. 2022 Feb 23;12:800605. doi: 10.3389/fneur.2021.800605Amiri P, Kazeminasab S, Nejadghaderi SA, et al. Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front Neurol. 2022 Feb 23;12:800605. doi: 10.3389/fneur.2021.800605Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022 Feb 1;163(2):e293e309. doi: 10.1097/j.pain.0000000000002275Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022 Feb 1;163(2):e293e309. doi: 10.1097/j.pain.0000000000002275Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019 Nov;37(4):631-49. doi: 10.1016/j.ncl.2019.06.001Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019 Nov;37(4):631-49. doi: 10.1016/j.ncl.2019.06.001Ayzenberg I, Katsarava Z, Sborowski A, et al; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012 Apr;32(5):37381. doi: 10.1177/0333102412438977Ayzenberg I, Katsarava Z, Sborowski A, et al; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012 Apr;32(5):37381. doi: 10.1177/0333102412438977Steiner TJ, Stovner LJ, Jensen R, et al. Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0Steiner TJ, Stovner LJ, Jensen R, et al. Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018 Feb 21;19(1):17. doi: 10.1186/s10194-018-0846-2Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018 Feb 21;19(1):17. doi: 10.1186/s10194-018-0846-2Кирьянова ЕА, Табеева ГР. Гормональная терапия менструально-ассоциированной мигрени: за и против. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):6975. doi: 10.14412/2074-2711-2022-1-69-75Kiryanova EA, Tabeeva GR. Hormone therapy for menstrual-associated migraine: pros and cons. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):69-75. doi: 10.14412/2074-2711-2022-1-69-75 (In Russ.).Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14. doi: 10.1038/s41582-02100509-5Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14. doi: 10.1038/s41582-02100509-5Lucas C, Geraud G, Valade D, et al. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache. 2006 May;46(5):715-25. doi: 10.1111/j.15264610.2006.00430.xLucas C, Geraud G, Valade D, et al. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache. 2006 May;46(5):715-25. doi: 10.1111/j.15264610.2006.00430.xLipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992 Jun;152(6):1273-8. doi: 10.1001/archinte.152.6.1273Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992 Jun;152(6):1273-8. doi: 10.1001/archinte.152.6.1273Lipton RB, Bigal ME, Diamond M, et al, AMPP Advisory Group: Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-9. doi: 10.1212/01.wnl.0000252808.97649.21Lipton RB, Bigal ME, Diamond M, et al, AMPP Advisory Group: Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-9. doi: 10.1212/01.wnl.0000252808.97649.21Lipton RB, Manack AN, Serrano D, Buse DC. Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study. J Headache Pain. 2013;14(Suppl 1):P201. doi: 10.1186/1129-2377-1-S14-P201Lipton RB, Manack AN, Serrano D, Buse DC. Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study. J Headache Pain. 2013;14(Suppl 1):P201. doi: 10.1186/1129-2377-1-S14-P201Ковальчук НА, Кирьянова ЕА, Табеева ГР. Приверженность терапии пациентов с мигренью (по данным интернетопроса). Неврология, нейропсихиатрия, психосоматика. 2021;13(4):81-7. doi: 10.14412/2074-2711-2021-4-81-87Kovalchuk NA, Kiryanova EA, Tabeeva GR. Medication adherence in migraine patients (data of an online survey). Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(4):817. doi: 10.14412/2074-2711-2021-4-81-87 (In Russ.).Мигрень. Клинические рекомендации МЗ РФ. 2021. [Migren'. Klinicheskie rekomendatsii MZ RFMigraine. Clinical recommendations of the Ministry of Health of the Russian Federation]. 2021 (In Russ.)].VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69. doi: 10.1001/jama.2021.7939VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69. doi: 10.1001/jama.2021.7939Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidencebased guideline update: pharmacologic treat ment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24;78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidencebased guideline update: pharmacologic treat ment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24;78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi: 10.1111/head.12499Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi: 10.1111/head.12499Nicolas S, Nicolas D. Triptans. Treasure Island (FL): StatPearls Publishing; 2022.Nicolas S, Nicolas D. Triptans. Treasure Island (FL): StatPearls Publishing; 2022.Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs: lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12 (12):E1180. doi: 10.3390/pharmaceutics12121180Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs: lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12 (12):E1180. doi: 10.3390/pharmaceutics12121180Табеева ГР, Амелин АВ, Ахмадеева ЛР и др. Оптимизация купирования приступов мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):126-33. doi: 10.14412/2074-2711-2023-2-126-133Tabeeva GR, Amelin AV, Akhmadeeva LR, et al. Optimization of migraine attacks relief. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):126-33. doi: 10.14412/2074-27112023-2-126-133 (In Russ.).Johnson B, Freitag FG. New Approaches to Shifting the Migraine Treatment Paradigm. Front Pain Res (Lausanne). 2022 Sep 6;3:873179. doi: 10.3389/fpain.2022.873179Johnson B, Freitag FG. New Approaches to Shifting the Migraine Treatment Paradigm. Front Pain Res (Lausanne). 2022 Sep 6;3:873179. doi: 10.3389/fpain.2022.873179Maassen Van Den Brink A, Saxena PR. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache. 2004;44(Suppl 1):S13-S19. doi: 10.1111/j.15264610.2004.04104.xMaassen Van Den Brink A, Saxena PR. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache. 2004;44(Suppl 1):S13-S19. doi: 10.1111/j.15264610.2004.04104.xAhn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain. 2005;115(1-2):1-4. doi: 10.1016/j.pain.2005.03.008Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain. 2005;115(1-2):1-4. doi: 10.1016/j.pain.2005.03.008Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. doi: 10.1186/s10194-022-01502-zSacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. doi: 10.1186/s10194-022-01502-zCharleston Iv L, Burke JF. Do racial/ethnic disparities exist in recommended migraine treatments in US ambulatory care? Cephalalgia. 2018 Apr;38(5):876-82. doi: 10.1177/0333102417716933. Epub 2017 Jun 26.Charleston Iv L, Burke JF. Do racial/ethnic disparities exist in recommended migraine treatments in US ambulatory care? Cephalalgia. 2018 Apr;38(5):876-82. doi: 10.1177/0333102417716933. Epub 2017 Jun 26.Diamond S, Bigal ME, Silberstein S, et al. Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache. 2007 Mar;47(3):355-63. doi: 10.1111/j.15264610.2006.00631.x. Erratum in: Headache. 2007 Oct;47(9):1365.Diamond S, Bigal ME, Silberstein S, et al. Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache. 2007 Mar;47(3):355-63. doi: 10.1111/j.15264610.2006.00631.x. Erratum in: Headache. 2007 Oct;47(9):1365.Ковальчук НА, Гузий ЕА, Табеева ГР. Особенности пациентов с частой эпизодической и хронической мигренью. Доктор.Ру. 2022;21(4):13-8. doi: 10.31550/1727-2378-2022-21-4-13-18Kovalchuk NA, Guziy EA, Tabeeva GR. Features of patients with frequent episodic and chronic migraine. Doctor.Ru. 2022;21(4):13-8. doi: 10.31550/1727-23782022-21-4-13-18 (In Russ.).Lipton RB, Munjal S, Buse DC, et al. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. Headache. 2019 Sep;59(8):1310-23. doi: 10.1111/head.13588Lipton RB, Munjal S, Buse DC, et al. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. Headache. 2019 Sep;59(8):1310-23. doi: 10.1111/head.13588Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013 Sep;53(8):1300-11. doi: 10.1111/head.12154. Epub 2013 Jul 23.Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013 Sep;53(8):1300-11. doi: 10.1111/head.12154. Epub 2013 Jul 23.Табеева ГР, Осипова ВВ, Филатова ЕГ и др. Диагностика и лечение лекарственноиндуцированной головной боли: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):4-13. doi: 10.14412/2074-27112022-1-4-13Tabeeva GR, Osipova VV, Filatova EG, et al. Evaluation and treatment of medication-overuse headache: Russian experts' guidelines. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):4-13. doi: 10.14412/2074-27112022-1-4-13 (In Russ.).Viana M, Genazzani AA, Terrazzino S, et al. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33(11):891-6. doi: 10.1177/0333102413480756Viana M, Genazzani AA, Terrazzino S, et al. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33(11):891-6. doi: 10.1177/0333102413480756Ferrari A, Pinetti D, Bertolini A, et al. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur J Clin Pharmacol. 2008;64(5):489-95. doi: 10.1007/s00228-0070443-9Ferrari A, Pinetti D, Bertolini A, et al. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur J Clin Pharmacol. 2008;64(5):489-95. doi: 10.1007/s00228-0070443-9Cady RK, Vause CV, Ho TW, et al. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49(9):1258-66. doi: 10.1111/j.1526-4610.2009.01523.xCady RK, Vause CV, Ho TW, et al. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49(9):1258-66. doi: 10.1111/j.1526-4610.2009.01523.xFerrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001 Nov 17;358(9294):1668-75. doi: 10.1016/S0140-6736(01)06711-3Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001 Nov 17;358(9294):1668-75. doi: 10.1016/S0140-6736(01)06711-3Cameron C, Kelly S, Hsieh SC. Triptans in the acute treatment of migraine: A systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221-35. doi: 10.1111/head.12601Cameron C, Kelly S, Hsieh SC. Triptans in the acute treatment of migraine: A systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221-35. doi: 10.1111/head.12601Block GA, Goldstein J, Polis A. On behalf of the Rizatriptan Multicenter Study Groups. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache. 1998 Nov-Dec;38(10):764-71.Block GA, Goldstein J, Polis A. On behalf of the Rizatriptan Multicenter Study Groups. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache. 1998 Nov-Dec;38(10):764-71.Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet. 2001;40(3):189-205. doi: 10.2165/00003088200140030-00004Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet. 2001;40(3):189-205. doi: 10.2165/00003088200140030-00004Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/1D agonists: insights into migraine pathophysiology using rizatriptan. Neurology. 2000;55(9 Suppl 2):S8-14.Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/1D agonists: insights into migraine pathophysiology using rizatriptan. Neurology. 2000;55(9 Suppl 2):S8-14.Dooley M, Faulds D. Rizatriptan: a review of its efficacy in the management of migraine. Drugs. 1999 Oct;58(4):699-723. doi: 10.2165/00003495-199958040-00013Dooley M, Faulds D. Rizatriptan: a review of its efficacy in the management of migraine. Drugs. 1999 Oct;58(4):699-723. doi: 10.2165/00003495-199958040-00013Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ. The anti-migraine 5HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guineapigs. Br J Pharmacol. 2001 Aug;133(7):1029-34. doi: 10.1038/sj.bjp.0704162Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ. The anti-migraine 5HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guineapigs. Br J Pharmacol. 2001 Aug;133(7):1029-34. doi: 10.1038/sj.bjp.0704162Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol. 1997;328:37-40. doi: 10.1016/s0014-2999(97)83024-5Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol. 1997;328:37-40. doi: 10.1016/s0014-2999(97)83024-5Hargreaves RJ, Lines CR, Rapoport AM, et al. Ten years of rizatriptan: from development to clinical science and future directions. Headache. 2009 Feb;49 Suppl 1:S3-20. doi: 10.1111/j.1526-4610.2008.01335.xHargreaves RJ, Lines CR, Rapoport AM, et al. Ten years of rizatriptan: from development to clinical science and future directions. Headache. 2009 Feb;49 Suppl 1:S3-20. doi: 10.1111/j.1526-4610.2008.01335.xFerrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia. 2001;21:129-36. doi: 10.1046/j.1468-2982.2001.00169.xFerrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia. 2001;21:129-36. doi: 10.1046/j.1468-2982.2001.00169.xBelsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res. 2001;4:105-25.Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res. 2001;4:105-25.Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology. 1998 Sep;51(3):77381. doi: 10.1212/wnl.51.3.773Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology. 1998 Sep;51(3):77381. doi: 10.1212/wnl.51.3.773Сергеев АВ, Табеева ГР, Филатова ЕГ и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116Sergeev AV, Tabeeva GR, Filatova EG, et al. Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116 (In Russ.).Rapoport AM, Tepper SJ, Sheftell FD, et al. Which triptan for which patient? Neurol Sci. 2006 May;27 Suppl 2:S123-9. doi: 10.1007/s10072-006-0586-yRapoport AM, Tepper SJ, Sheftell FD, et al. Which triptan for which patient? Neurol Sci. 2006 May;27 Suppl 2:S123-9. doi: 10.1007/s10072-006-0586-yDe Boer I, Verhagen IE, Souza MNP, Ashina M. Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia. 2023 Feb;43(2):3331024221143773. doi: 10.1177/03331024221143773De Boer I, Verhagen IE, Souza MNP, Ashina M. Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia. 2023 Feb;43(2):3331024221143773. doi: 10.1177/03331024221143773Cortelli P, Allais G, Benedetto C. Overview of Triptans in the Treatment of Acute Migraine. Eur Neurol Rev. 2017;12(2):71-7. doi: 10.17925/ENR.2017.12.02.71Cortelli P, Allais G, Benedetto C. Overview of Triptans in the Treatment of Acute Migraine. Eur Neurol Rev. 2017;12(2):71-7. doi: 10.17925/ENR.2017.12.02.71Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, Lopez-Gil A; START 10 Study Group. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin Ther. 2003 Jul;25(7):2053-69. doi: 10.1016/s0149-2918(03)80204-7Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, Lopez-Gil A; START 10 Study Group. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin Ther. 2003 Jul;25(7):2053-69. doi: 10.1016/s0149-2918(03)80204-7McMahon G. Triptans for migraine: how should triptans be used? 2010. Available from: http://blogs.nejm.org/now/index.php/ triptans-for-migraine-how-shouldtriptans-be-used/2010/07/02/ (accessed 23.02.2017).McMahon G. Triptans for migraine: how should triptans be used? 2010. Available from: http://blogs.nejm.org/now/index.php/ triptans-for-migraine-how-shouldtriptans-be-used/2010/07/02/ (accessed 23.02.2017).Bigal M, Rapoport A, Aurora S, et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007 Apr;47(4):475-9. doi: 10.1111/j.1526-4610.2007.00752.xBigal M, Rapoport A, Aurora S, et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007 Apr;47(4):475-9. doi: 10.1111/j.1526-4610.2007.00752.xLeroux E, Buchanan A, Lombard L, et al. Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review. Adv Ther. 2020 Dec;37(12):4765-96. doi: 10.1007/s12325-020-01494-9Leroux E, Buchanan A, Lombard L, et al. Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review. Adv Ther. 2020 Dec;37(12):4765-96. doi: 10.1007/s12325-020-01494-9Olesen A, Schytz HW, Ostrowski SR, et al. Low adherence to the guideline for the acute treatment of migraine. Sci Rep. 2022 May 19;12(1):8487. doi: 10.1038/s41598-022-12545-2Olesen A, Schytz HW, Ostrowski SR, et al. Low adherence to the guideline for the acute treatment of migraine. Sci Rep. 2022 May 19;12(1):8487. doi: 10.1038/s41598-022-12545-2Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002 Jan;42 Suppl 1:3-9. doi: 10.1046/j.15264610.2002.0420s1003.xLipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002 Jan;42 Suppl 1:3-9. doi: 10.1046/j.15264610.2002.0420s1003.xCutrer FM, Goadsby PJ, Ferrari MD, et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). Clin Ther. 2004 Sep;26(9):1533-45. doi: 10.1016/j.clinthera.2004.09.011Cutrer FM, Goadsby PJ, Ferrari MD, et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). Clin Ther. 2004 Sep;26(9):1533-45. doi: 10.1016/j.clinthera.2004.09.011Gerth WC, McCarroll KA, Santanello NC, et al. Patient satisfaction with rizatriptan vs other triptans: Direct head-to head comparisons. Int J Clin Pract. 2001 Oct;55(8):552-6.Gerth WC, McCarroll KA, Santanello NC, et al. Patient satisfaction with rizatriptan vs other triptans: Direct head-to head comparisons. Int J Clin Pract. 2001 Oct;55(8):552-6.Pascual J, Fite B, Lopez-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache. 2002 Feb;42(2):93-8. doi: 10.1046/j.1526-4610.2002.02024.xPascual J, Fite B, Lopez-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache. 2002 Feb;42(2):93-8. doi: 10.1046/j.1526-4610.2002.02024.xХохлов АЛ, Лейкин ЗН. Сравнительное клиническое исследование фармакокинетики и биоэквивалентности препаратов ризатриптана Релонова и Максалт. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(8):1-7. doi: 10.17116/jnevro20231230811Khokhlov AL, Leykin ZN. Comparative clinical study of pharmacokinetics and bioequivalence of Relonova and Maxalt. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2023;123(8):1-7. doi: 10.17116/jnevro20231230811 (In Russ.).

The authors declare that there are no conflicts of interest present.